KDT-501

KDT-501 is an orally bioavailable small molecule modulator of the taste receptor type 2 (TAS2R) family, specifically derived from hops (humulus lupulus) as a tetrahydro-isohumulone derivative. Developed by KinDex Pharmaceuticals, it is designed to treat metabolic and endocrine disorders by targeting TAS2Rs expressed in extra-oral tissues such as adipose tissue and the gastrointestinal tract. KDT-501 acts to improve insulin sensitivity, reduce systemic inflammation, and regulate lipid metabolism. In clinical and preclinical studies, it has demonstrated the ability to increase adiponectin levels, decrease pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α), and lower plasma triglycerides. Its primary development focus includes polycystic ovary syndrome (PCOS), where it helps normalize testosterone levels and ovulation, as well as nonalcoholic steatohepatitis (NASH) and type 2 diabetes.

Other names

tetrahydro-isohumulone derivativeisohumulone derivative